Benzinga | Sep 20, 2021 08:19AM EDT

Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12

Oppenheimer analyst Leland Gershell initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Outperform rating and announces Price Target of $12.